CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS
Embodiments of the disclosure include methods and compositions related to targeting of CD5-expressing cells with particular engineered receptors. In specific embodimetns, NK cells are specifically engineered to bind the CD5 antigen using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the CD5-targeting CARs also express particular a suicide gene and/or one or more particular cytokines..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 21. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
REZVANI KATY [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-21, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
EP4322992 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003107663 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003107663 | ||
| 003 | DE-627 | ||
| 005 | 20240426155519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003107663 | ||
| 035 | |a (EPA)EP4322992 | ||
| 035 | |a (EPA)83640731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a REZVANI KATY |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-21, Last update posted on www.tib.eu: 2024-04-23, Last updated: 2024-04-26 | ||
| 520 | |a Embodiments of the disclosure include methods and compositions related to targeting of CD5-expressing cells with particular engineered receptors. In specific embodimetns, NK cells are specifically engineered to bind the CD5 antigen using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the CD5-targeting CARs also express particular a suicide gene and/or one or more particular cytokines. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHPALL ELIZABETH |e verfasserin |4 aut | |
| 700 | 0 | |a BASAR RAFET |e verfasserin |4 aut | |
| 700 | 0 | |a DAHER MAY |e verfasserin |4 aut | |
| 700 | 0 | |a ACHARYA SUNIL |e verfasserin |4 aut | |
| 700 | 0 | |a UPRETY NADIMA |e verfasserin |4 aut | |
| 700 | 0 | |a NUNEZ CORTES ANA KAREN |e verfasserin |4 aut | |
| 700 | 0 | |a ENSLEY EMILY |e verfasserin |4 aut | |
| 700 | 0 | |a MARIN COSTA DAVID |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 21. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83640731/publication/EP4322992A1?q=EP4322992 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 02 | ||